Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The principal objective of the study is the evaluation of the role of Human Papilloma Virus (HPV) in plantar warts (prevalence, genotype), resistant or not, treated or not, cured or not. This epidemiological study is an ancillary study of the prospective, randomized controlled, clinical study VRAIE (sponsor: APHP) comparing 5 usual strategies in the management of plantar warts.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Salicylate ointment | patients included in VRAIE study, treated with salicylate ointment (VRAIE study, NCT01059110) |
| |
| Imiquimod | patients included in VRAIE study, treated with Imiquimod (VRAIE study, NCT01059110) |
| |
| 5-Fluoro-Uracil | patients included in VRAIE study, treated with 5-Fluoro-Uracil (VRAIE study, NCT01059110) |
| |
| Cryotherapy | patients included in VRAIE study, treated with cryotherapy (VRAIE study, NCT01059110) |
| |
| placebo | patients included in VRAIE study, receiving placebo (VRAIE study, NCT01059110) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| skin flakes collection | Genetic | viral status assessment of skin flakes |
|
| Measure | Description | Time Frame |
|---|---|---|
| Detection of HPV viral DNA on samples | research of positive HPV status | up to Day 90 |
| Measure | Description | Time Frame |
|---|---|---|
| Distribution of viral genotypes | number of samples containing one or more viral type (type 1, 2, 4 or mix) | up to Day 90 |
| Clinical remission defined | complete remission of wards confirmed by the physician, no later than day 90 |
Not provided
Inclusion Criteria:
Male or female patient aged 18 years or more.
Clinical evaluation
Number of warts lower than 10 on the 2 feet and total diameter of warts lower than 10 cm, whether previously treated or not
In treated patients, all potentially active treatment on warts since at least one month should be stopped.
Effective contraception for women of childbearing age
Immunocompetent patients
Patient with one or more warts on soles and board feet.
Patient affiliated to the French social security.viral
Exclusion Criteria:
Not provided
Not provided
Not provided
2000 skin flakes to be collected from patients included in VRAIE study
Not provided
| Name | Affiliation | Role |
|---|---|---|
| François Aubin, MD PhD | Centre Hospitalier Universitaire de Besancon | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| up to Day 90 |
| Viral remission for patients with wards resistant to treatments | viral status modification from negative to positive between day 0 and day 30, day 60 or no more than day 90. | up to Day 90 |
| Clinical relapse | 21 months |